Other

Lymphotec Inc.

Humantec Ltd.

Yasuyuki Kuroiwa

Kenzo Bamba

Norio Shimizu

Teruaki Sekine

Kiminari Ito

Tomohiro Morio

Tomohiro Yamaguchi

HLA matched activated lymphocytes in mononuclear cells separated from peripheral blood or umbilical cord blood are proliferated and activated. After separating and collecting, the HLA matched activated lymphocytes are employed as the main component of a composition for promoting survival of transplanted hematopoietic stem cells. The obtained composition is widely usable in, for instance, prevention of survival failure of transplanted hematopoietic stem cells and therapy for promoting the survival thereof. Although the dose of the composition varies depending on the age, conditions, etc. of a patient, a humanized antibody is administered in a dose of from 0.2 to 20 ml/kg/day to mammals including humans. The composition is administered by intravenous injection either once a day (single administration or continuous administration) or intermittently once to 3 times in a week or once in 2 or 3 weeks.

Method for producing a composition for promoting survival of transplanted hematopoietic stem cell

Activated lymphocytes derived from cord blood are excellently effective for preventing and treating various types of tumors and various types of infection. With interleukin 2 and/or anti-CD3 antibody, the lymphocytes derived from the cord blood is prepared by segregating lymphocytes from the cord blood and proliferating the segregated lymphocytes directly in vitro or segregating monocytes from cord blood and proliferating the monocytes in vitro. Also, the cord blood-derived activated lymphocytes can be effectively used for preventing recurrence of the diseases and promoting the take of stem cells or other organs.

Cord blood-derived activated lymphocytes, preparations containing said lymphocytes as main ingredient and method and kit for producing said preparations

Compositions or medicaments comprising allogenic activated-CD4&plus; cells as the main ingredient, which are attributable to an organ or bone marrow transplantation donor, have an extremely beneficial effect for preventing recidivation of a tumor and remedying various infections such as viral infections, and autoimmune diseases such as phagocytosis, without causing any serious GVHD. The allogenic activated-CD4&plus; cells can be produced by separating lymphocyte cells or CD4&plus; cells from peripheral blood of the donor or removing CD8&plus; cells from the peripheral blood of the donor by using anti-CD8&plus; antibodies to obtain CD4&plus; cells and proliferating the CD4&plus; cells thus prepared in proliferation activator.

Compositions comprising, as the main ingredient, allogenic activated-C4&plus; cells and method for producing and using the same

Growing community of inventors

Ibaraki, Japan

Yasuyuki Kuroiwa